Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $40.80.

Several research firms recently commented on GMAB. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Zacks Research upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Genmab A/S in a research note on Wednesday, October 15th. Wall Street Zen cut shares of Genmab A/S from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Guggenheim upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a research note on Tuesday, September 23rd.

Genmab A/S Trading Down 7.9%

GMAB opened at $30.54 on Thursday. The company has a 50 day moving average of $28.14 and a 200 day moving average of $23.47. The company has a market cap of $19.61 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 1.85 and a beta of 0.98. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $33.65.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. Research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Orbis Allan Gray Ltd lifted its stake in Genmab A/S by 102.8% in the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock worth $111,816,000 after purchasing an additional 2,895,179 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after buying an additional 2,084,966 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock valued at $24,634,000 after buying an additional 665,893 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Genmab A/S by 111.5% during the 1st quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company’s stock valued at $21,149,000 after buying an additional 569,345 shares in the last quarter. Finally, ABC Arbitrage SA purchased a new stake in shares of Genmab A/S during the 2nd quarter valued at $9,236,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.